Background illustration for clinical trials search

Paid Clinical Trials Fresno

Discover 161 paid clinical trials in Fresno, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 161

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for

Advanced Esophageal Adenocarcinoma,

Location: Fresno CA, Modesto CA, San Jose CA, Santa Clara CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06203600

Phase2, Phase3, Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Fresno CA, Modesto CA, San Jose CA, Santa Clara CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Fresno CA, Modesto CA, San Jose CA, Santa Clara CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Fresno CA, San Jose CA, Santa Clara CA, San Leandro CA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: Fresno CA, Modesto CA, San Jose CA, Stockton CA,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for

Metastatic Nasopharyngeal Carcinoma,

Location: Fresno CA, Modesto CA, San Jose CA, Santa Clara CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06029270

Phase2, Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Fresno CA, Modesto CA, San Jose CA, Santa Clara CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for

Advanced Lung Non-Squamous Non-Small Cell Carcinoma,

Location: Fresno CA, Modesto CA, San Jose CA, Stockton CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04181060

Phase3, Recruiting

Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

for

Post Procedural Erythema

Location: Fresno CA, Granite Bay CA, West Hollywood CA,

Sponsor: Acorn Biolabs Inc.

Sex: All

Age: 18+

Code: NCT06477172

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Location: Fresno CA, Madera CA, Modesto CA, San Jose CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 5 - 60

Code: NCT05675410

Phase3, Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for

Castration Levels of Testosterone,

Location: Fresno CA, Clovis CA, Modesto CA, San Luis Obispo CA,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT03678025

Phase3, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: Fresno CA, Modesto CA, San Jose CA, Arroyo Grande CA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

for

Pulmonary Hypertension, Interstitial Lung Disease

Location: Fresno CA, Phoenix AZ, Bend OR, Denver CO,

Sponsor: Liquidia Technologies, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06129240

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for

End Stage Kidney Disease

Location: Fresno CA, Salinas CA, Oxnard CA, Granada Hills CA,

Sponsor: CSL Behring

Sex: All

Age: 18+

Code: NCT05485961

Phase2, Phase3, Recruiting

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

for

IgA Nephropathy

Location: Fresno CA, Stanford CA, San Francisco CA, Orange CA,

Sponsor: Calliditas Therapeutics AB

Sex: All

Age: 18+

Code: NCT06712407

Recruiting

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

for

Hematuria - Cause Not Known

Location: Fresno CA, Los Angeles CA, Dallas TX, Madison WI,

Sponsor: Pacific Edge Limited

Sex: All

Age: 18 - 70+

Code: NCT06394869

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Location: Fresno CA, Bakersfield CA, Santa Monica CA,

Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06510374

Phase3, Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

for

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Location: Fresno CA, Duarte CA, San Diego CA, Springfield OR,

Sponsor: Dendreon

Sex: Male

Age: 18+

Code: NCT06134232

Phase2, Recruiting

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

for

Prostate Adenocarcinoma

Location: Fresno CA, San Francisco CA, Portland OR, Milwaukee WI,

Sponsor: Alessa Therapeutics Inc.

Sex: Male

Age: 21+

Code: NCT06257693

Phase1, Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

for

Pulmonary Arterial Hypertension

Location: Fresno CA, Stanford CA, Sacramento CA, Los Angeles CA,

Sponsor: Gossamer Bio USA, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06274801

Phase3, Recruiting

Paid Clinical Trials Fresno

Filter results

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Interested in new trials?

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)